The invention relates to a pharmaceutical composition as a therapeutic agent for ischemic disease comprising a compound of the formula ##STR1## wherein R.sup.1 is carbamoyl substituted with morpholino (lower) alkyl, thiomorpholino(lower)alkyl or lower alkylamino(lower)alkyl; or ureido substituted with lower alkylamino(lower)alkyl; and R.sup.2 is phenyl substituted with nitro, and R.sup.4 is lower alkyl; or R.sup.2 is lower alkyl, and R.sup.4 is phenyl substituted with nitro; with proviso that R.sup.1 is carbamoyl substituted with thiomorpholino(lower)alkyl or lower alkylamino(lower)alkyl; or ureido substituted with lower alkylamino(lower)alkyl when R.sup.4 is lower alkyl; or its salt, as an active ingredient, in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient.
本发明涉及一种药物组合物,作为缺血性疾病的治疗剂,包括式中的化合物:##STR1##其中,R.sup.1是以
吗啡环(lower)烷基、
硫代
吗啡环(lower)烷基或(lower)烷基
氨(lower)烷基取代的
氨基甲酰基;或以(lower)烷基
氨(lower)烷基取代的
脲基;R.sup.2是以硝基取代的苯基,R.sup.4是(lower)烷基;或R.sup.2是(lower)烷基,R.sup.4是以硝基取代的苯基;但前提是当R.sup.4是(lower)烷基时,R.sup.1是以
硫代
吗啡环(lower)烷基或(lower)烷基
氨(lower)烷基取代的
氨基甲酰基或以(lower)烷基
氨(lower)烷基取代的
脲基;或其盐,作为活性成分,与药学上可接受的、基本无毒的载体或赋形剂相结合。